Esperion Therapeutics (ESPR) Holder Meditor Group LTD Increased Position by $1.81 Million as Share Price Rose; Schlumberger LTD (SLB) Stock Declined While Horan Capital Advisors Has Lowered Its Stake

May 22, 2018 - By Marguerite Chambers

Schlumberger Limited (NYSE:SLB) Logo

Horan Capital Advisors Llc decreased its stake in Schlumberger Ltd (SLB) by 20.07% based on its latest 2017Q4 regulatory filing with the SEC. Horan Capital Advisors Llc sold 6,056 shares as the company’s stock declined 4.39% with the market. The institutional investor held 24,115 shares of the oilfield services and equipment company at the end of 2017Q4, valued at $1.63 million, down from 30,171 at the end of the previous reported quarter. Horan Capital Advisors Llc who had been investing in Schlumberger Ltd for a number of months, seems to be less bullish one the $102.13B market cap company. The stock decreased 1.73% or $1.3 during the last trading session, reaching $73.73. About 5.63M shares traded. Schlumberger Limited (NYSE:SLB) has declined 16.28% since May 22, 2017 and is downtrending. It has underperformed by 27.83% the S&P500.

Meditor Group Ltd increased its stake in Esperion Therapeutics Inc (ESPR) by 1.22% based on its latest 2017Q4 regulatory filing with the SEC. Meditor Group Ltd bought 27,900 shares as the company’s stock rose 22.41% while stock markets declined. The institutional investor held 2.32 million shares of the health care company at the end of 2017Q4, valued at $152.94M, up from 2.29M at the end of the previous reported quarter. Meditor Group Ltd who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.06B market cap company. The stock increased 4.88% or $1.85 during the last trading session, reaching $39.74. About 1.22M shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since May 22, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Meditor Group Ltd, which manages about $776.92M US Long portfolio, decreased its stake in Exelixis Inc (NASDAQ:EXEL) by 932,100 shares to 16.48 million shares, valued at $501.13M in 2017Q4, according to the filing.

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Globenewswire.com which released: “ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class …” on May 18, 2018, also Benzinga.com with their article: “Esperion Shares Plunge After Cholesterol-Lowering Drug’s Phase 3 Results Stir Safety Concerns” published on May 02, 2018, Businesswire.com published: “Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Esperion Therapeutics, Inc.” on May 22, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Digitaljournal.com and their article: “NASDAQ:ESPR Shareholder Notice: Lawsuit Alleges Misleading Statements by Esperion Therapeutics, Inc” published on May 22, 2018 as well as Businesswire.com‘s news article titled: “ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Esperion …” with publication date: May 22, 2018.

Among 19 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 3 Sell and 6 Hold. Therefore 53% are positive. Esperion Therapeutics had 68 analyst reports since July 28, 2015 according to SRatingsIntel. As per Wednesday, June 29, the company rating was downgraded by Barclays Capital. The firm has “Buy” rating by Citigroup given on Tuesday, February 28. The stock has “Buy” rating by Cowen & Co on Tuesday, March 27. Cowen & Co initiated it with “Buy” rating and $64.0 target in Thursday, September 7 report. Needham maintained the shares of ESPR in report on Monday, March 20 with “Strong Buy” rating. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Neutral” rating by Citigroup on Monday, November 14. WallachBeth Capital initiated Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, October 26 with “Buy” rating. The rating was maintained by Chardan Capital Markets with “Neutral” on Friday, February 26. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Neutral” rating by UBS on Wednesday, February 21. The rating was downgraded by JP Morgan to “Neutral” on Wednesday, June 29.

Investors sentiment decreased to 1.33 in Q4 2017. Its down 0.34, from 1.67 in 2017Q3. It fall, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Atika Mgmt Ltd Llc owns 1.43% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 56,000 shares. Moreover, Deutsche Bank & Trust Ag has 0.01% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Rhenman & Prtn Asset Mgmt invested in 3.44% or 386,626 shares. Keybank National Association Oh owns 4,991 shares for 0% of their portfolio. Wasatch Advsrs stated it has 693,265 shares. Pentwater LP has invested 0.84% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Fmr Llc stated it has 1.25M shares. Hamilton Lane Advsr Limited Liability Co reported 115,344 shares or 3.92% of all its holdings. Barclays Public Ltd has 65,697 shares. Sg Americas Securities Llc holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 3,023 shares. Morgan Stanley reported 0% stake. Partner Mngmt Ltd Partnership stated it has 0.92% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Toth Advisory accumulated 30 shares. Ameritas Prtnrs reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Among 39 analysts covering Schlumberger Limited. (NYSE:SLB), 32 have Buy rating, 1 Sell and 6 Hold. Therefore 82% are positive. Schlumberger Limited. had 148 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating by FBR Capital given on Monday, January 22. Citigroup maintained the shares of SLB in report on Monday, October 5 with “Buy” rating. The company was upgraded on Tuesday, May 10 by Guggenheim. On Wednesday, April 20 the stock rating was downgraded by Standpoint Research to “Hold”. RBC Capital Markets maintained Schlumberger Limited (NYSE:SLB) on Wednesday, July 5 with “Buy” rating. Cowen & Co maintained Schlumberger Limited (NYSE:SLB) on Monday, April 25 with “Outperform” rating. The stock has “Outperform” rating by Oppenheimer on Monday, October 19. The rating was maintained by BMO Capital Markets with “Buy” on Tuesday, September 5. The rating was upgraded by Standpoint Research to “Hold” on Wednesday, August 26. The company was maintained on Friday, October 6 by Cowen & Co.

Horan Capital Advisors Llc, which manages about $224.00 million and $153.71 million US Long portfolio, upped its stake in Abbvie Inc (NYSE:ABBV) by 27,087 shares to 66,717 shares, valued at $8.55M in 2017Q4, according to the filing.

Since January 22, 2018, it had 3 buys, and 3 insider sales for $6.93 million activity. $192,900 worth of stock was bought by Al Mogharbel Khaled on Wednesday, March 28. On Wednesday, May 16 Jaramillo Claudia sold $218,049 worth of Schlumberger Limited (NYSE:SLB) or 3,000 shares. Another trade for 75,000 shares valued at $5.91M was made by AYAT SIMON on Wednesday, January 24. Schorn Patrick bought $323,950 worth of stock. Guild Howard sold $1.96M worth of Schlumberger Limited (NYSE:SLB) on Monday, January 22.

More recent Schlumberger Limited (NYSE:SLB) news were published by: Seekingalpha.com which released: “Trade War Relief Rally – Cramer’s Mad Money (5/21/18)” on May 22, 2018. Also Seekingalpha.com published the news titled: “Schlumberger Keeps Chugging Along” on April 23, 2018. Bizjournals.com‘s news article titled: “Two Houston companies join Fortune 500 this year” with publication date: May 21, 2018 was also an interesting one.

Schlumberger Limited (NYSE:SLB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>